Skip to content

Study · Randomized controlled trial · n = 20 · 2013

10 results

Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.

Hermansen K, Bækdal TA, Düring M, Pietraszek A, Mortensen LS, Jørgensen H, Flint A

Diabetes, obesity & metabolism11 Jun 2013Cited by 121 (Europe PMC)

PMID23683069 (opens in a new tab)DOI10.1111/dom.12133 (opens in a new tab)PepBankPUB-23683069
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide 1.8 mg reduced mean postprandial triglyceride AUC(0-8h) versus placebo after a fat-rich meal.

    In plain wordsIn adults with type 2 diabetes, liraglutide lowered blood fat after a fatty meal compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial triglyceride AUC(0-8h)
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    1.8 mg once daily (weekly escalation from 0.6 mg) · subcutaneous · 3 weeksAs given in this study (human).

    Measurements

    AUC(0-8h) treatment ratio
    0.72 ratio
    triglyceride, liraglutide/placebo

    Source sentences

    Summary
    After 3 weeks, mean postprandial triglyceride (AUC(0-8h) liraglutide/placebo treatment-ratio 0.72, 95% CI [0.62-0.83], p = 0.0004)
    2 context sentences
    Summary · context
    After each 3-week period, a standardized fat-rich meal was provided, and the effects of liraglutide on triglyceride (primary endpoint AUC(0-8h)), apolipoprotein B48, non-esterified fatty acids, glycaemic responses and gastric emptying were assessed.
    Summary · context
    In a cross-over trial, patients with T2DM (n = 20, 18-75 years, BMI 18.5-40 kg/m²) were randomized to once-daily subcutaneous liraglutide (weekly dose escalation from 0.6 to 1.8 mg) and placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide 1.8 mg reduced mean postprandial apolipoprotein B48 AUC(0-8h) versus placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide lowered apolipoprotein B48 after a fatty meal compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial apolipoprotein B48 AUC(0-8h)
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    1.8 mg once daily (weekly escalation from 0.6 mg) · subcutaneous · 3 weeksAs given in this study (human).

    Measurements

    AUC(0-8h) ratio
    0.65 ratio
    apolipoprotein B48, liraglutide/placebo

    Source sentences

    Summary
    and apolipoprotein B48 (AUC(0-8h) ratio 0.65 [0.58-0.73], p < 0.0001)
    1 context sentence
    Summary · context
    In a cross-over trial, patients with T2DM (n = 20, 18-75 years, BMI 18.5-40 kg/m²) were randomized to once-daily subcutaneous liraglutide (weekly dose escalation from 0.6 to 1.8 mg) and placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide 1.8 mg reduced postprandial triglyceride iAUC(0-8h) and Cmax versus placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide lowered the incremental and peak blood fat after a fatty meal compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial triglyceride iAUC(0-8h) and Cmax
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    1.8 mg once daily (weekly escalation from 0.6 mg) · subcutaneous · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    significantly decreased with liraglutide 1.8 mg versus placebo, as did iAUC(0-8h) and C(max) (p < 0.001).
    1 context sentence
    Summary · context
    In a cross-over trial, patients with T2DM (n = 20, 18-75 years, BMI 18.5-40 kg/m²) were randomized to once-daily subcutaneous liraglutide (weekly dose escalation from 0.6 to 1.8 mg) and placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide 1.8 mg reduced postprandial apolipoprotein B48 iAUC(0-8h) and Cmax versus placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide lowered the incremental and peak apolipoprotein B48 after a fatty meal compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial apolipoprotein B48 iAUC(0-8h) and Cmax
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    1.8 mg once daily (weekly escalation from 0.6 mg) · subcutaneous · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    significantly decreased with liraglutide 1.8 mg versus placebo, as did iAUC(0-8h) and C(max) (p < 0.001).
    1 context sentence
    Summary · context
    In a cross-over trial, patients with T2DM (n = 20, 18-75 years, BMI 18.5-40 kg/m²) were randomized to once-daily subcutaneous liraglutide (weekly dose escalation from 0.6 to 1.8 mg) and placebo.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide did not significantly change non-esterified fatty acids versus placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide did not significantly change free fatty acids compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeNon-esterified fatty acids
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    1.8 mg once daily (weekly escalation from 0.6 mg) · subcutaneous · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    No significant treatment differences were observed for non-esterified fatty acids.
    1 context sentence
    Summary · context
    In a cross-over trial, patients with T2DM (n = 20, 18-75 years, BMI 18.5-40 kg/m²) were randomized to once-daily subcutaneous liraglutide (weekly dose escalation from 0.6 to 1.8 mg) and placebo.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide significantly reduced mean postprandial glucose AUC(0-8h) and Cmax versus placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide lowered blood sugar after a fatty meal compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial glucose AUC(0-8h) and Cmax
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg once daily (weekly escalation from 0.6 mg) · subcutaneous · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Mean postprandial glucose and glucagon AUC(0-8h) and C(max) were significantly reduced with liraglutide versus placebo
    1 context sentence
    Summary · context
    In a cross-over trial, patients with T2DM (n = 20, 18-75 years, BMI 18.5-40 kg/m²) were randomized to once-daily subcutaneous liraglutide (weekly dose escalation from 0.6 to 1.8 mg) and placebo.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide significantly reduced mean postprandial glucagon AUC(0-8h) and Cmax versus placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide lowered glucagon after a fatty meal compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial glucagon AUC(0-8h) and Cmax
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    1.8 mg once daily (weekly escalation from 0.6 mg) · subcutaneous · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Mean postprandial glucose and glucagon AUC(0-8h) and C(max) were significantly reduced with liraglutide versus placebo
    1 context sentence
    Summary · context
    In a cross-over trial, patients with T2DM (n = 20, 18-75 years, BMI 18.5-40 kg/m²) were randomized to once-daily subcutaneous liraglutide (weekly dose escalation from 0.6 to 1.8 mg) and placebo.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide did not change the postprandial gastric emptying rate versus placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide did not change how fast the stomach emptied compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeGastric emptying rate
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    1.8 mg once daily (weekly escalation from 0.6 mg) · subcutaneous · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Postprandial gastric emptying rate [assessed by paracetamol absorption (liquid phase) and the ¹³C-octanoate breath test (solid phase)] displayed no treatment differences.
    1 context sentence
    Summary · context
    In a cross-over trial, patients with T2DM (n = 20, 18-75 years, BMI 18.5-40 kg/m²) were randomized to once-daily subcutaneous liraglutide (weekly dose escalation from 0.6 to 1.8 mg) and placebo.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, mean low-density lipoprotein cholesterol decreased significantly with liraglutide versus placebo.

    In plain wordsIn adults with type 2 diabetes, LDL cholesterol was lower with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseLDL cholesterol
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    1.8 mg once daily (weekly escalation from 0.6 mg) · subcutaneous · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Mean low-density lipoprotein and total cholesterol decreased significantly with liraglutide versus placebo.
    1 context sentence
    Summary · context
    In a cross-over trial, patients with T2DM (n = 20, 18-75 years, BMI 18.5-40 kg/m²) were randomized to once-daily subcutaneous liraglutide (weekly dose escalation from 0.6 to 1.8 mg) and placebo.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, mean total cholesterol decreased significantly with liraglutide versus placebo.

    In plain wordsIn adults with type 2 diabetes, total cholesterol was lower with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal cholesterol
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    1.8 mg once daily (weekly escalation from 0.6 mg) · subcutaneous · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Mean low-density lipoprotein and total cholesterol decreased significantly with liraglutide versus placebo.
    1 context sentence
    Summary · context
    In a cross-over trial, patients with T2DM (n = 20, 18-75 years, BMI 18.5-40 kg/m²) were randomized to once-daily subcutaneous liraglutide (weekly dose escalation from 0.6 to 1.8 mg) and placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT00993304

A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics

Novo Nordisk A/Sn = 20Oct 2009 to Dec 2010

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 26 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.